Showing 3501-3510 of 18631 results for "".
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
https://reachmd.com/programs/acc-action-center/targeting-cardiac-energetics-with-cardiac-mitotrope-in-nonobstructive-hcm/24346/ACC.24 - There is an unmet treatment need for nonobstructive hypertrophic cardiomyopathy (nHCM). Martin Maron shares the results of IMPROVE-HCM, which evaluated the efficacy and safety of the novel cardiac mitotrope ninerafaxstat in nHCM.The Patient-Clinician Connection in Managing CKD-aP
https://reachmd.com/programs/cme/the-patient-clinician-connection-in-managing-ckd-ap/36302/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
https://reachmd.com/programs/cme/advancing-clinical-expertise-in-celmods-transforming-multiple-myeloma-treatment/35631/This activity will cultivate familiarity with the emerging CELMoD treatment class poised to transform the management of newly-diagnosed and R/R MM. With a higher affinity for cereblon than their predecessors, CELMoDs represent a new, distinct generation of immunomodulatory drugs with the potential tAn Expert’s Approach to a Difficult-to-Manage Condition: Breaking the rCDI Cycle with a Microbiome-Focused Strategy
https://reachmd.com/programs/medical-industry-feature/breaking-rcdi-cycle-microbiome-strategy/35918/Recurrent C. difficile infection (rCDI) presents a significant physical and emotional burden for both patients and caregivers. VOWST®(fecal microbiota spores, live-brpk) capsules is the only FDA-approved, orally administered microbiome therapeutic used following antibiotics to prevent rCDI. Hear froTranslating Clinical Data Into Multidisciplinary Practice for ES-SCLC
https://reachmd.com/programs/cme/translating-clinical-data-into-multidisciplinary-practice-for-es-sclc/37878/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Case Review: Targets Are Met—Can You Stick the Landing?
https://reachmd.com/programs/cme/case-review-targets-are-metcan-you-stick-the-landing/51488/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Direct from the Heart Failure Clinic: Novel Device Therapy for Patients with HFrEF
https://reachmd.com/programs/cme/direct-from-the-heart-failure-clinic-novel-device-therapy-for-patients-with-hfref/14473/Learn about baroreflex activation therapy (BAT), an implantable, FDA-approved cardiac device that’s improving exercise capacity, QoL & more.Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-wclc-2025/37877/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
https://reachmd.com/programs/cme/asparaginase-based-treatment-young-adults-all/37193/Are you up to date on treatment strategies for young adults with acute lymphoblastic leukemia (ALL)? Evolving evidence and clinical guidelines now strongly support the use of asparaginase-based, pediatric-inspired regimens over traditional adult protocols for young adults with ALL. However, many patBeyond GDMT: Timely Consideration of Barostim in Heart Failure
https://reachmd.com/programs/cme/beyond-gdmt-timely-consideration-of-barostim-in-heart-failure/29820/Hear experts discuss best practices for identifying candidates for Barostim™ and the timing for adding a medical device to your patient’s treatment plan.